Analytical Data
-
Gene name
PTGDR
- Application
-
Alternative Names
PTGDR；Prostaglandin D2 receptor
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q13258
-
Expression Region
1-359aa
-
AA Sequence
MKSPFYRCQNTTSVEKGNSAVMGGVLFSTGLLGNLLALGLLARSGLGWCSRRPLRPLPSVFYMLVCGLTVTDLLGKCLLSPVVLAAYAQNRSLRVLAPALDNSLCQAFAFFMSFFGLSSTLQLLAMALECWLSLGHPFFYRRHITLRLGALVAPVVSAFSLAFCALPFMGFGKFVQYCPGTWCFIQMVHEEGSLSVLGYSVLYSSLMALLVLATVLCNLGAMRNLYAMHRRLQRHPRSCTRDCAEPRADGREASPQPLEELDHLLLLALMTVLFTMCSLPVIYRAYYGAFKDVKEKNRTSEEAEDLRALRFLSVISIVDPWIFIIFRSPVFRIFFHKIFIRPLRYRSRCSNSTNMESSL
-
Molecular Weight
40.2 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PTGDR (Prostaglandin D2 Receptor) is a G-protein-coupled receptor that plays a pivotal role in mediating the effects of prostaglandin D2, particularly in the context of allergic responses, inflammation, and regulation of sleep. The interest in PTGDR research has grown due to its potential implications in various pathological conditions, including asthma, sleep disorders, and neurodegenerative diseases. Researchers have increasingly focused on the structural and functional aspects of PTGDR to elucidate its signaling mechanisms and interaction with ligands. The development of recombinant PTGDR proteins has enabled the exploration of its pharmacological properties and has provided insights into designing specific agonists or antagonists that could modulate its activity. Furthermore, understanding the molecular dynamics and conformational changes of PTGDR upon ligand binding is essential for drug discovery efforts aimed at addressing the therapeutic challenges associated with PTGDR-related diseases. As the field progresses, continued research into the biophysical properties and biological functions of PTGDR will pave the way for novel therapeutic strategies targeting this receptor, potentially leading to significant advancements in treating various inflammatory and allergic conditions.
